Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis.
Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis.
复制标题
DOI：
10.1155/2012/591654
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Lu F
中科院分区：
文献类型：
--
作者：
Dong H;Wang N;Zhao L;Lu F
目标。目的评价黄连素治疗2型糖尿病(T2 DM)的疗效和安全性。方法：研究方法。黄连素与生活方式改变、安慰剂和/或口服降糖干预治疗T2 DM的随机试验包括在内。研究人群特征和结果由两位评价者独立提取。对可获得的数据进行Meta分析。结果。这项研究包括14个随机试验，涉及1068名参与者。方法质量普遍较低。与使用或不使用安慰剂的生活方式改变相比，黄连素和生活方式改变的联合干预显示出显著的降血糖和降血脂反应。与口服降糖药包括二甲双胍、格列吡嗪或罗格列酮相比，黄连素并没有表现出明显更好的血糖控制，但显示出温和的降血脂作用。与口服降糖药相比，黄连素的联合干预和相同的口服降糖药显示出更好的血糖控制。黄连素没有严重不良反应的报道。结论。黄连素对T2 DM患者的高血糖和血脂异常有较好的治疗作用。然而，由于黄连素治疗T2 DM的方法学质量低、样本量小、试验数量有限以及存在不确定的偏倚风险，因此应该仔细解释黄连素治疗T2 DM的证据。
Objectives. To assess the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus (T2DM). Methods. Randomized trials of berberine compared with lifestyle modification, placebo, and/or oral hypoglycaemics intervention on treating T2DM were included. Study population characteristics and outcome results were extracted independently by two reviewers. Meta-analyses were performed for data available. Results. Fourteen randomized trials, involving 1068 participants, were included in this study. Methodological quality was generally low. Compared with lifestyle modification with or without placebo, the cointervention of berberine and lifestyle modification showed significantly hypoglycaemic and antidyslipidemic response. Compared with oral hypoglycaemics including metformin, glipizide, or rosiglitazone, berberine did not demonstrate a significantly better glycaemic control but showed a mild antidyslipidemic effect. Compared with oral hypoglycaemic drugs, cointerventions with berberine and the same oral hypoglycaemics showed a better glycaemic control. No serious adverse effects from berberine were reported. Conclusions. Berberine appeared to be efficacious for treating hyperglycaemia and dyslipidemia in T2DM. However, the evidence of berberine for treating T2DM should be carefully interpreted due to the low methodological quality, small sample size, limited number of trials, and unidentified risks of bias.
登录
查看更多内容
影响因子：
158.5
作者：
Nissen, Steven E.;Wolski, Kathy
通讯作者：
Wolski, Kathy
DOI：
10.2174/187221411794351879
发表时间：
2011-01-01
期刊：
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY
影响因子：
--
作者：
Ho, Josephine;Leung, Alexander K. C.;Rabi, Doreen
通讯作者：
Rabi, Doreen
影响因子：
7.2
作者：
Linn, Yeh-ching;Lu, Jiahui;Ng, Han-seong
通讯作者：
Ng, Han-seong
影响因子：
3.3
作者：
El-Kaissi, Samer;Sherbeeni, Suphia
通讯作者：
Sherbeeni, Suphia
影响因子：
--
作者：
Covington, M. B.
通讯作者：
Covington, M. B.